Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1

Conditions

Multiple Myeloma 192Lymphoma 102Lymphoma, Non-Hodgkin 90Leukemia, Myeloid, Acute 89Precursor Cell Lymphoblastic Leukemia-Lymphoma 81Myelodysplastic Syndromes 81Hodgkin Disease 67Leukemia 66Neoplasms, Plasma Cell 65Lymphoma, Large B-Cell, Diffuse 59Leukemia, Lymphocytic, Chronic, B-Cell 58Lymphoma, Mantle-Cell 52Lymphoma, Follicular 49Burkitt Lymphoma 39Lymphoma, Large-Cell, Immunoblastic 35Lymphoma, B-Cell, Marginal Zone 34Myeloproliferative Disorders 30Recurrence 28Hematologic Neoplasms 28Neuroblastoma 25Leukemia, Myelogenous, Chronic, BCR-ABL Positive 25Leukemia, Myeloid, Accelerated Phase 24Graft vs Host Disease 23Leukemia, Myelomonocytic, Chronic 22Leukemia, Myeloid, Chronic-Phase 22Congenital Abnormalities 21Immunoglobulin Light-chain Amyloidosis 20Dendritic Cell Sarcoma, Interdigitating 19Primary Myelofibrosis 18Waldenstrom Macroglobulinemia 17

Interventions

Ipilimumab 6tremelimumab 5durvalumab 5Nivolumab 3Capecitabine 3Radiotherapy 2Radiation 2Paclitaxel 2CTLA-4 Antigen 2Blood Specimen Collection 2relatlimab 1poly ICLC 1lenvatinib 1folfirinox 1balstilimab 1Vaccines 1Vaccination 1Surgical Procedures, Operative 1Radiosurgery 1Platinum 1Peptides 1Pemetrexed 1Oxaliplatin 1Opdualag 1Monophenol Monooxygenase 1Melphalan 1Leucovorin 1Immunotherapy 1Fluorouracil 1Docetaxel 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Diabetes Mellitus, Insulin-Dependent, 12 × Melphalan × Clear all
NCT02716805 2022-10-12

Phase 1 Study of Tremelimumab, Durvalumab, High-dose Chemotherapy, + Autologous Stem Cell Transplant

Ludwig Institute for Cancer Research

Phase 1 Terminated
6 enrolled 11 charts
Plasma cell

Diabetes Mellitus, Insulin-Dependent, 12, Multiple Myeloma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡